Ionis Pharmaceuticals IONS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.4%-0.2pp | 98.3%-0.1pp | 98.8%+0.1pp | 98.9%+0.3pp | 98.5%-0.2pp | |
| Operating margin | -33.3%+32.6pp | -40.4%+26.9pp | -28.8%+17.4pp | -28.2%+16.6pp | -65.9%-15.8pp | |
| Net margin | -30.9%+33.0pp | -40.4%+24.0pp | -26.5%+18.2pp | -28.4%+16.6pp | -63.9%-14.3pp | |
| EBITDA margin | -32%+32.2pp | -39.1%+26.6pp | -27.6%+27.2pp | -27%+19.7pp | -64.3%-12.5pp | |
| Returns | ||||||
| Return on equity | -67.6%+51.0pp | -70.8%+22.3pp | -40%+33.3pp | -59.9%+45.8pp | -118.6%-20.4pp | |
| Return on assets | -10.4%+6.0pp | -11.7%+3.5pp | -8.4%+3.5pp | -9.5%+3.5pp | -16.4%-2.8pp | |
| Return on invested capital | -51%+127pp | -24.2%+91.4pp | -32.4%+101pp | -40.7%+178pp | -177.7%-19.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.1× | 0.3×+0.1× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Inventory turnover | 2×+1.5× | 1.4×+0.3× | 0.6×+0.2× | 0.6×+0.1× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.1×-5.6× | 3.8×-4.6× | 2.8×-6.1× | 2.9×-4.7× | 9.7×+2.3× | |
| Quick ratio | 4.1×-5.5× | 3.8×-4.6× | 2.8×-6.0× | 2.9×-4.7× | 9.6×+2.3× | |
| Cash ratio | 0.2×-0.8× | 0.5×-0.3× | 0.4×-0.7× | 0.3×-0.6× | 1.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 1.4×+1.1× | 5×+4.7× | 1.4×+1.1× | 1.3×+0.5× | 0.3×-0.4× | |
| Debt-to-assets | 0.2×+0.1× | 0.7×+0.6× | 0.3×+0.2× | 0.3×+0.2× | 0.1×0.0× | |
| Interest coverage | -19.2×+8.6× | -22.1×+5.8× | -16.7×+9.4× | -16.1×+6.5× | -27.9×-0.6× | |
| Per Share | ||||||
| Book value per share | $2.98-0.6% | $3.06-22.3% | $3.87-13.2% | $3.46+91.8% | $3.00+47.1% | |
| Valuation | ||||||
| Market capitalization | $12.4B+159% | $12.81B+132% | $10.43B+78.3% | $6.31B-9.0% | $4.8B-23.2% | |
| Enterprise value | $12.92B+175% | $14.91B+171% | $10.98B+91.8% | $6.81B-0.7% | $4.69B-23.2% | |
| Price / sales | 11.7×+5.0× | 13.6×+5.7× | 10.8×+3.5× | 6.7×-1.8× | 6.7×-1.4× | |
| Price / book | 25.2×+15.2× | 26.2×+16.8× | 16.9×+8.0× | 10×-16.3× | 10.1×-11.0× | |
| EV / sales | 12.2×+5.7× | 15.8×+8.0× | 11.4×+4.2× | 7.2×-1.2× | 6.5×-1.3× | |
| Earnings yield | -2.6%+6.9pp | -3%+5.2pp | -2.5%+3.7pp | -4.3%+1.0pp | -9.6%-3.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ionis Pharmaceuticals's profit margins?
- Ionis Pharmaceuticals (IONS) runs a 98.4% gross margin and a -33.3% operating margin, with a -30.9% net margin.
- Where do Ionis Pharmaceuticals's ratios come from?
- Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
